#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Acute myeloid leukaemia Stargardt's disease Neonatal asphyxia Autoinflammation with infantile enterocolitis Atopic keratoconjunctivitis Fibrous dysplasia of bone Nephropathy Hypoparathyroidism Glycogen storage disease type II Chronic cutaneous lupus erythematosus Alport's syndrome Infertility male Post transplant lymphoproliferative disorder Rhabdomyosarcoma Acquired ATTR amyloidosis More trials…

    Learn about Rare Diseases

    Hereditary ataxia – Diagnostics Small intestine leiomyosarcoma – Trials in Disease Alport’s syndrome – Diagnostics Soft tissue sarcoma – Life with Disease Nephrotic syndrome Antithrombin III deficiency Myelodysplastic syndrome with excess blasts Acquired haemophilia – Basic Information Vascular malformation Choroid melanoma – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Lifileucel Sym025 Cart45Ra-Nkg2D Cells Triptorelin Alrefimotide Pf-06480605 BW-20805 Follitropin Delta Specific Nucleic Acid Sna-Her1 Cefalexin Monohydrate Ataluren Abbv-668 Ursodoxicoltaurine Clozapine Givinostat VENT-03 NALDEMEDINE Omalizumab Topotecan Hydrochloride Ly3537982 More therapies…

    Learn about Your Condition

    Infective uveitis Oxygen saturation Vulvovaginal pruritus Interstitial lung disease Cataract Ewing's sarcoma metastatic Craniocerebral injury Mesothelioma malignant Vulval cancer recurrent Neuromuscular scoliosis Anal cancer Hypertension Pharyngeal cancer stage III Embolism Coronary artery disease More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Study on Tebentafusp and Liver Radiotherapy for Patients with Metastatic Uveal Melanoma HLA A*02:01 Positive

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Uveal melanoma
    Investigated Drugs:
    • Tebentafusp
    Italy

  • Efficacy and Safety Study of Paltusotine for Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumors

    Recruiting

    3 1
    Investigated Drugs:
    • Paltusotine
    Belgium Denmark France Germany Ireland Italy +4

  • Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • BLEXIMENIB
    • Azacitidine
    • Venetoclax
    Austria Belgium Czechia Denmark France Germany +6

  • Evaluation of SB-007 Safety and Efficacy in Patients with Stargardt Disease Type 1 (STGD1) Caused by ABCA4 Gene Mutations

    Recruiting

    2 1 1
    Investigated Drugs:
    • ADENO-ASSOCIATED VIRUS VECTOR SEROTYPE 8 ENCODING THE ABCA4 PROTEIN, C-REGION
    • ADENO-ASSOCIATED VIRUS VECTOR SEROTYPE 8 ENCODING THE ABCA4 PROTEIN, N-REGION
    Belgium Germany

  • Study of mRNA-4157 and Pembrolizumab for Patients with Metastatic Melanoma

    Recruiting

    2 1 1
    Investigated Drugs:
    • Mrna-4157
    • Pembrolizumab
    France Germany Greece Italy Poland Portugal +1

  • Evaluation of Hydrocortisone, Octreotide, and Teres Ligament Patch Combination to Prevent Complications After Pancreatoduodenectomy in Patients with Pancreatic Head Cancer or IPMN

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Octreotide Acetate
    • Hydrocortisone
    Belgium Denmark Finland Italy The Netherlands Norway +1
Previous Page
1 … 169 170 171 172 173 … 1,648
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!